Discontinued — last reported Q4 '24
Edwards Lifesciences United States — Goodwill acquired during the year (Note 10) remained flat by 0.0% to $107.30M in Q4 2024 compared to the prior quarter.
Higher values indicate aggressive inorganic growth strategies in the U.S. market, while zero values suggest a focus on organic growth or lack of domestic M&A.
Measures the amount of goodwill recognized specifically from business acquisitions completed within the United States se...
Commonly reported by companies in high-growth sectors like medical devices that frequently acquire smaller innovators.
ew_segment_united_states_goodwill_acquired_during_the_year_note_10| FY'23 | FY'24 | |
|---|---|---|
| Value | $0.00 | $429.20M |